Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Peter Kamper

Showing results (11-20 of 38) with videos related to

Pageof 4
Sort By:
European Journal of Haematology|October 14, 2014
Relationship of intratumoural protein expression patterns to age and Epstein-Barr virus status in classical Hodgkin lymphomaMaja Ludvigsen, Peter Kamper, Stephen J Hamilton-Dutroit, et al.
Leukemia & Lymphoma|May 18, 2022
Factors associated with risk and prognosis of intensive care unit admission in patients with acute leukemia: a Danish nationwide cohort studyCecilie Velsoe Maeng, Christian Fynbo Christiansen, Kathleen Dori Liu, et al.
Scientific Reports|August 18, 2025
Lymph node transcriptomic profiles suggest susceptibility to bleomycin-induced pulmonary toxicity in classic hodgkin lymphomaMaja Dam Andersen, Marie Hairing Enemark, Kristina Lystlund Lauridsen, et al.
European Journal of Haematology|May 13, 2015
Tumour-associated mast cells in classical Hodgkin's lymphoma: correlation with histological subtype, other tumour-infiltrating inflammatory cell subsets and outcomeMaja D Andersen, Peter Kamper, Patricia S Nielsen, et al.
Blood|April 21, 2011
Proteomic analysis identifies galectin-1 as a predictive biomarker for relapsed/refractory disease in classical Hodgkin lymphomaPeter Kamper, Maja Ludvigsen, Knud Bendix, et al.
Leukemia & Lymphoma|December 3, 2024
Proteomic profiling identifies classic Hodgkin lymphoma patients at risk of bleomycin pulmonary toxicityMaja Dam Andersen, Katharina Wolter, Marie Hairing Enemark, et al.
Blood Advances|January 4, 2018
High proportions of PD-1<sup>+</sup> and PD-L1<sup>+</sup> leukocytes in classical Hodgkin lymphoma microenvironment are associated with inferior outcomePeter Hollander, Peter Kamper, Karin Ekstrom Smedby, et al.
British Journal of Haematology|April 9, 2022
Late recurrence of lymphoid malignancies after initial treatment for Hodgkin lymphoma - A study from the Danish Lymphoma RegistryMaja Dam Andersen, Stephen Hamilton-Dutoit, Lena Modvig, et al.
Cancer Medicine|July 3, 2019
Distribution of hospital care among pediatric and young adult Hodgkin lymphoma survivors-A population-based cohort study from Sweden and DenmarkIngrid Glimelius, Annika Englund, Klaus Rostgaard, et al.
Acta Oncologica (Stockholm, Sweden)|August 2, 2017
Hodgkin lymphoma in children, adolescents and young adults - a comparative study of clinical presentation and treatment outcomeAnnika Englund, Ingrid Glimelius, Klaus Rostgaard, et al.
Pageof 4

Showing results (11-20 of 38) with videos related to

Sort By:
Pageof 4
European Journal of Haematology|October 14, 2014
Relationship of intratumoural protein expression patterns to age and Epstein-Barr virus status in classical Hodgkin lymphomaMaja Ludvigsen, Peter Kamper, Stephen J Hamilton-Dutroit, et al.
Leukemia & Lymphoma|May 18, 2022
Factors associated with risk and prognosis of intensive care unit admission in patients with acute leukemia: a Danish nationwide cohort studyCecilie Velsoe Maeng, Christian Fynbo Christiansen, Kathleen Dori Liu, et al.
Scientific Reports|August 18, 2025
Lymph node transcriptomic profiles suggest susceptibility to bleomycin-induced pulmonary toxicity in classic hodgkin lymphomaMaja Dam Andersen, Marie Hairing Enemark, Kristina Lystlund Lauridsen, et al.
European Journal of Haematology|May 13, 2015
Tumour-associated mast cells in classical Hodgkin's lymphoma: correlation with histological subtype, other tumour-infiltrating inflammatory cell subsets and outcomeMaja D Andersen, Peter Kamper, Patricia S Nielsen, et al.
Blood|April 21, 2011
Proteomic analysis identifies galectin-1 as a predictive biomarker for relapsed/refractory disease in classical Hodgkin lymphomaPeter Kamper, Maja Ludvigsen, Knud Bendix, et al.
Leukemia & Lymphoma|December 3, 2024
Proteomic profiling identifies classic Hodgkin lymphoma patients at risk of bleomycin pulmonary toxicityMaja Dam Andersen, Katharina Wolter, Marie Hairing Enemark, et al.
Blood Advances|January 4, 2018
High proportions of PD-1<sup>+</sup> and PD-L1<sup>+</sup> leukocytes in classical Hodgkin lymphoma microenvironment are associated with inferior outcomePeter Hollander, Peter Kamper, Karin Ekstrom Smedby, et al.
British Journal of Haematology|April 9, 2022
Late recurrence of lymphoid malignancies after initial treatment for Hodgkin lymphoma - A study from the Danish Lymphoma RegistryMaja Dam Andersen, Stephen Hamilton-Dutoit, Lena Modvig, et al.
Cancer Medicine|July 3, 2019
Distribution of hospital care among pediatric and young adult Hodgkin lymphoma survivors-A population-based cohort study from Sweden and DenmarkIngrid Glimelius, Annika Englund, Klaus Rostgaard, et al.
Acta Oncologica (Stockholm, Sweden)|August 2, 2017
Hodgkin lymphoma in children, adolescents and young adults - a comparative study of clinical presentation and treatment outcomeAnnika Englund, Ingrid Glimelius, Klaus Rostgaard, et al.
Pageof 4